The 2 analysts offering 12-month price forecasts for Acer Therapeutics Inc have a median target of 9.00, with a high estimate of 10.00 and a low estimate of 8.00. The median estimate represents a +326.54% increase from the last price of 2.11.
The current consensus among 5 polled investment analysts is to Hold stock in Acer Therapeutics Inc. This rating has held steady since February, when it was downgraded from a Buy rating.Move your mouse over past months for detail
Earnings and Sales Forecasts
Earnings per Share -$0.40
Reporting Date May 19
Earnings per Share
Move your mouse over a quarter or year to see how estimates have changed over time.